Clinical trials: Semaglutide
Obesity
Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity
Obesity is a growing global health problem that affects people of all ages. It can lead to serious health issues such as cardiovascular disease, insulin resistance, inflammation, and reduced physical function.
- Trial name
- NCT07319975
- Testing
- Semaglutide, Tirzepatide, Tirzepatide+Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Istanbul Galata University
Kidney Disease, Chronic, Diabetes
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population.
- Conditions
- Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
- Trial name
- GUARD-1 (NCT07017270)
- Testing
- Semaglutide Pen
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Unity Health Toronto
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Metabolic Syndrome
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly…
- Conditions
- Obesity, Metabolic Syndrome, Brown Adipose Tissue
- Trial name
- BAT-Sema (NCT07621640)
- Testing
- Semaglutide (Wegovy®), ¹⁸FDG-PET/CT with cold stimulation, Liver MRI (PDFF + MRE)
- Where
- 2 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Hallym University
Diabetes Mellitus, Type 2
A Trial to Evaluate Safety, Feasibility and Efficacy of Endoscopic Duodenal PEF Therapy
The objective of this study is to evaluate the safety, feasibility and efficacy of pulsed electric field induced duodenal mucosal regeneration (with the Endogenex System en Gen 2 Device) combined with a GLP-1 receptor agonist…
- Trial name
- EMINENT-2 (NCT05984238)
- Testing
- PEF therapy using the Endogenex Device, Semaglutide, 1.0 mg/mL
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Healthy, Obesity
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
This study is open to adults between 18 and 55 years of age who are living with overweight or obesity. People with a body mass index (BMI) from 27 to 40 kg/m2 can join the study.
- Trial name
- NCT05751226
- Testing
- BI 1820237, semaglutide, BI 456906
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors.
- Trial name
- NCT06780449
- Testing
- Cagrilintide, Semaglutide
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men
This study looks at different tablets with a new study medicine called semaglutide. It is to treat diabetes. The aim of the study is to find out how much study medicine from 4 different tablets is taken up in the body.
- Trial name
- NCT03638778
- Testing
- Semaglutide 3 mg, Semaglutide 7 mg, Semaglutide B 3 mg
- Where
- Germany
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type2Diabetes, ASCVD
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D)…
- Trial name
- PRECIDENTD (NCT05390892)
- Testing
- SGLT2 inhibitor, GLP-1 receptor agonist
- Where
- 36 sites in United States
- Volunteers
- 6,000 people
- Sponsor
- Brigham and Women's Hospital
Overweight, Obesity
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake.
- Trial name
- NCT06267092
- Testing
- No treatment given, Cagrilintide and Semaglutide
- Where
- Germany
- Volunteers
- 164 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
The aim of this study is to evaluate whether exposure to semaglutide influences the risk of pancreatic cancer in patients with type 2 diabetes.
- Trial name
- NCT04572165
- Testing
- Ozempic®, Active Comparator, Rybelsus®
- Where
- Denmark
- Volunteers
- 194,928 people
- Sponsor
- Novo Nordisk A/S
Opioid Use Disorder
Semaglutide for Helping Opioid Recovery
The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching…
- Trial name
- SHORE (NCT06639464)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Brigham and Women's Hospital
Stage 1 Diabetes Mellitus, Type 1
GLP-1 RA for Stage 1 Type 1 Diabetes
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes.
- Trial name
- NCT07430332
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy
The purpose of the study is to look at the change in blood sugar levels in people with type 2 diabetes who change their treatment from DPP4i to oral semaglutide.
- Trial name
- DOORS (NCT05755360)
- Testing
- Semaglutide
- Where
- 25 sites in Italy
- Volunteers
- 291 people
- Sponsor
- Novo Nordisk A/S
Obesity
The Effect of Semaglutide on the Intestinal Flora in Obesity
For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide…
- Trial name
- NCT07323134
- Testing
- Semaglutide Injection
- Volunteers
- 40 people
- Sponsor
- Beijing Chao Yang Hospital
Pre-Diabetes, Weight, Body
Prevention of Progression of Prediabetes, Obesity and CV Risk
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.
- Conditions
- Pre-Diabetes, Weight, Body, Cardiovascular Diseases
- Trial name
- Pre-DM (NCT06446531)
- Testing
- Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S
Healthy
The Effect of Semaglutide on Pituitary Function
The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.
- Trial name
- NCT04865744
- Testing
- Semaglutide 7 MG Oral Tablet, Semaglutide 14 MG Oral Tablet
- Where
- Estonia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Tartu